Plasma and whole blood pharmacokinetics of topiramate: the role of carbonic anhydrase
Tóm tắt
Từ khóa
Tài liệu tham khảo
Altman, P.L., 1961. In: Dittmer, D.S. (Eds.), Blood and Other Body Fluids. Fed. Am. Soc. Exp. Biol., Washington, DC, pp. 65, 109.
Bialer, 2004, Pharmacokinetic interactions of topiramate, Clin. Pharmacokinet., 43, 763, 10.2165/00003088-200443120-00001
Cammer, 1976, Brain carbonic anhydrase: activity in isolated myelin and the effect of hexachlorophene, J. Neurochem., 27, 165, 10.1111/j.1471-4159.1976.tb01559.x
Casini, 2003, Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/sulfamides with isozymes I, II and IV, Bioorg. Med. Chem. Lett., 13, 841, 10.1016/S0960-894X(03)00029-5
Cheng, 1973, Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 percent inhibition (I50) of an enzymatic reaction, Biochem. Pharmacol., 22, 3099, 10.1016/0006-2952(73)90196-2
Dodgson, 2000, Topiramate as an inhibitor of carbonic anhydrase isozymes, Epilepsia, 41, S35, 10.1111/j.1528-1157.2000.tb06047.x
Doose, 1996, Single-dose pharmacokinetics and effect of food on the bioavailability of topiramate, a novel antiepileptic drug, J. Clin. Pharmacol., 36, 884, 10.1002/j.1552-4604.1996.tb04754.x
Doose, 2002, Topiramate—chemistry, biotransformation and pharmacokinetics, 727
Epstein, 1978, Carbonic anhydrase inhibitor side effects, Arch. Ophthalmol., 95, 1378, 10.1001/archopht.1977.04450080088009
Forster, 1975, Time course of exchanges between red cells and extracellular fluid during CO2 uptake, J. Appl. Physiol., 38, 710, 10.1152/jappl.1975.38.4.710
Francesco, 2002, Nonaromatic sulfonamide group as an ideal anchor for potent human carbonic anhydrase inhibitors: role of hydrogen-bonding networks in ligand binding and drug design, J. Med. Chem., 45, 3583, 10.1021/jm011131t
Garnett, 2000, Clinical pharmacology of topiramate: a review, Epilepsia, 41, S61, 10.1111/j.1528-1157.2000.tb02174.x
Gibaldi, 1982
Johannessen, 2003, Therapeutic drug monitoring of the newer antiepileptic drugs, Ther. Drug Monit., 25, 347, 10.1097/00007691-200306000-00016
Khalifah, 1991, Carbonic anhydrase kinetics and molecular function, 49
Maseree, 2002, Carbonic anhydrase inhibitors: anticonvulsant sulfonamides incorporating valproyl and other lipophilic moieties, J. Med. Chem., 45, 312, 10.1021/jm0109199
Nayak, 1994, Estimation of the absolute bioavailability of topiramate in human without intravenous data, J. Clin. Pharmacol., 34, 1029
Perucca, 1999, The clinical pharmacokinetics of the new antiepileptic drugs, Epilepsia, 40, S7, 10.1111/j.1528-1157.1999.tb02088.x
Pocker, 1967, The catalytic versatility of erythrocyte carbonic anhydrase. III. Kinetic studies of the enzyme-catalyzed hydrolysis of p-nitrophenyl acetate, Biochemistry, 668, 10.1021/bi00855a005
Porter, 2004, Antiseizure drugs, 379
Riffitts, 1999, A capillary gas chromatographic assay with nitrogen phosphorus detection for the quantification of topiramate in human plasma, urine and whole blood, J. Pharm. Biomed. Anal., 19, 363, 10.1016/S0731-7085(98)00137-X
Rowland, 1995
Shank, 1994, Topiramate: preclinical evaluation of a structurally novel anticonvulsant, Epilepsia, 35, 450, 10.1111/j.1528-1157.1994.tb02459.x
Swenson, 1978, A quantitative analysis of CO2 transport at rest and during maximal exercise, Respir. Physiol., 35, 129, 10.1016/0034-5687(78)90018-X
Talbot, 1998, A study of the release of carbon dioxide gas from carbonated beverages, Microscope, 46, 161
Thorslund, 1967, Studies of the esterase activity and the anion inhibition of bovine zinc and cobalt carbonic anhydrases, Eur. J. Biochem., 3, 117, 10.1111/j.1432-1033.1967.tb19504.x
Waugh, 2003, Topiramate as monotherapy in newly diagnosed epilepsy, CNS Drugs, 17, 985, 10.2165/00023210-200317130-00007
Wistrand, 1981, The importance of carbonic anhydrase B and C for the unloading of CO2 by the human erythrocyte, Acta Physiol. Scand., 113, 417, 10.1111/j.1748-1716.1981.tb06918.x